The Current Ratio as of September 2024 (TTM) for Zentalis Pharmaceuticals, Inc. (ZNTL) is 6.59

According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.59. This represents a change of -17.38% compared to the average of 7.98 of the last 4 quarters.

Zentalis Pharmaceuticals, Inc. (ZNTL) Historical Current Ratio (quarterly & annually)

How has ZNTL Current Ratio performed in the past?

The mean historical Current Ratio of Zentalis Pharmaceuticals, Inc. over the last ten years is 7.52. The current 6.59 Current Ratio has changed 8.66% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's Current Ratio was at its highest in in the September 2020 quarter at 15.59. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Zentalis Pharmaceuticals, Inc. (ZNTL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Zentalis Pharmaceuticals, Inc. (ZNTL) Average Current Ratio

How has ZNTL Current Ratio performed in the past?

The current Current Ratio of Zentalis Pharmaceuticals, Inc. (ZNTL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Zentalis Pharmaceuticals, Inc. (ZNTL) Current Ratio vs. Peers

How is ZNTL’s Current Ratio compared to its peers?

Zentalis Pharmaceuticals, Inc.’s Current Ratio is greater than Sana Biotechnology, Inc. (5.20), less than Olema Pharmaceuticals, Inc. (9.13), less than Cullinan Oncology, Inc. (28.87), greater than aTyr Pharma, Inc. (6.07), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Erasca, Inc. (16.79), greater than Day One Biopharmaceuticals, Inc. (4.09), less than Inozyme Pharma, Inc. (9.84), less than Syndax Pharmaceuticals, Inc. (10.50), less than Protagonist Therapeutics, Inc. (13.73), less than Revolution Medicines, Inc. (15.42), greater than Blueprint Medicines Corporation (3.71), less than Kymera Therapeutics, Inc. (8.45), less than iTeos Therapeutics, Inc. (18.08), less than Icosavax, Inc. (18.06), less than Mirati Therapeutics, Inc. (7.54), less than VectivBio Holding AG (9.14), less than Annexon, Inc. (21.81),

Build a custom stock screener for Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.